Axumin Pet Scan

Axumin fluciclovine f 18 injection is indicated for positron emission tomography pet imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen psa levels following prior treatment.

Axumin pet scan. For years we have been able to detect prostate cancer recurrences with psa but standard body and bone scans have been unable to determine the location of the cancer until the psa level is excessively elevated 10 to 30 or higher. Axumin is an fda approved medicare covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. Each milliliter contains up to 2 micrograms of fluciclovine 335 to 8200 mbq 9 to 221 mci fluciclovine f 18 at calibration time and date and 20 mg trisodium citrate in water for injection. Axumin based pet ct scans and detection of recurrent prostate cancer posted on april 30 2020 by sitemaster a new report from a relatively small single institution study has provided additional information about the utility of 18 f fluciclovine axumin pet ct scans in the detection of recurrent prostate cancer after definitive first line treatment.

An axumin scan may help. Image interpretation errors can occur with axumin pet imaging. Axumin fluciclovine f 18 is an advanced diagnostic imaging agent or radiotracer that s used with a positron emission tomography pet computed tomography ct scan for men who have had prior treatment for prostate cancer and now have elevated prostate specific antigen psa levels. The other potential application of the axumin scan apart from its usefulness for determining the area of psa relapse is for men who have undergone chemo hormonal treatment for advanced metastatic disease.

The suspicion is supported by high levels of psa in the blood following prior treatment. Axumin a 18 f fluciclovine injection is a molecular agent used in positron emission tomography pet imaging in men with suspected recurrent prostate cancer.